These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 7761042)

  • 41. [Indications critically evaluated: hormone-domain hot flashes].
    MMW Fortschr Med; 2003 Nov; 145(46):5-8. PubMed ID: 14699822
    [No Abstract]   [Full Text] [Related]  

  • 42. [The role of progestin in menopausal hormonal replacement therapy].
    Kauppila A
    Duodecim; 1996; 112(12):1097-103. PubMed ID: 10593011
    [No Abstract]   [Full Text] [Related]  

  • 43. Use of menopausal hormones in the United States, 1992 through June, 2003.
    Wysowski DK; Governale LA
    Pharmacoepidemiol Drug Saf; 2005 Mar; 14(3):171-6. PubMed ID: 15386701
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Menopause, estrogens, progestins, or their combination on body weight and anthropometric measures.
    Cagnacci A; Zanin R; Cannoletta M; Generali M; Caretto S; Volpe A
    Fertil Steril; 2007 Dec; 88(6):1603-8. PubMed ID: 17481628
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Estrogens, progestins and the bone].
    Ribot C
    Rev Prat; 1993 Dec; 43(20):2619-23. PubMed ID: 8146561
    [TBL] [Abstract][Full Text] [Related]  

  • 46. New hormonal therapies and regimens in the postmenopause: routes of administration and timing of initiation.
    Sitruk-Ware R
    Climacteric; 2007 Oct; 10(5):358-70. PubMed ID: 17852138
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of combined oral estrogen/progestogen preparation (Kliogest) on bone mineral density, plasma lipids and postmenopausal symptoms in HRT-naïve Thai women.
    Jirapinyo M; Theppisai U; Manonai J; Suchartwatnachai C; Jorgensen LN
    Acta Obstet Gynecol Scand; 2003 Sep; 82(9):857-66. PubMed ID: 12911449
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The rationale for low-dose hormonal therapy.
    Lobo RA
    Endocrine; 2004 Aug; 24(3):217-21. PubMed ID: 15542888
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Estrogen plus progestin, benefits and risks: the "Women's Health Initiative" trials.
    Keller KB; Lemberg L
    Am J Crit Care; 2005 Mar; 14(2):157-60. PubMed ID: 15728959
    [No Abstract]   [Full Text] [Related]  

  • 50. Management strategies for hormonal replacement therapy.
    Scharbo-DeHaan M
    Nurse Pract; 1994 Dec; 19(12):47-52, 55-7. PubMed ID: 7862347
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Hormonal therapy (HRT) in menopause].
    Ciszek-Doniec V
    Przegl Lek; 1999; 56(4):308-12. PubMed ID: 10494170
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The climacteric syndrome and its management].
    Keller PJ
    Schweiz Rundsch Med Prax; 1986 Mar; 75(12):328-32. PubMed ID: 3008291
    [No Abstract]   [Full Text] [Related]  

  • 53. [Prevention of osteoporosis by estrogens].
    Birkhäuser M
    Rev Med Suisse Romande; 1995 Feb; 115(2):113-20. PubMed ID: 7886365
    [No Abstract]   [Full Text] [Related]  

  • 54. Lower doses of oral estrogen and progestogens as treatment for postmenopausal women.
    Archer DF
    Semin Reprod Med; 2005 May; 23(2):188-95. PubMed ID: 15852205
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Estrogen treatment. Effective or dangerous in the climacteric and postmenopausal period?].
    Iversen OE
    Tidsskr Nor Laegeforen; 1989 Sep; 109(25):2531-4. PubMed ID: 2814970
    [No Abstract]   [Full Text] [Related]  

  • 56. Low-dose estrogen therapy for prevention of osteoporosis: working our way back to monotherapy.
    Richman S; Edusa V; Fadiel A; Naftolin F
    Menopause; 2006; 13(1):148-55. PubMed ID: 16607111
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hormonal treatment for the climacteric: alleviation of symptoms and prevention of postmenopausal disease.
    te Velde ER; van Leusden HA
    Lancet; 1994 Mar; 343(8898):654-8. PubMed ID: 7906817
    [No Abstract]   [Full Text] [Related]  

  • 58. Effects of hormone replacement therapy regimens on mammographic breast density: the role of progestins.
    Topal NB; Ayhan S; Topal U; Bilgin T
    J Obstet Gynaecol Res; 2006 Jun; 32(3):305-8. PubMed ID: 16764621
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [The climacteric--physiology or pathology?].
    Distler W
    Arch Gynecol Obstet; 1989; 245(1-4):947-52. PubMed ID: 2679445
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tibolone, transdermal estradiol or oral estrogen-progestin therapies: effects on circulating allopregnanolone, cortisol and dehydroepiandrosterone levels.
    Pluchino N; Genazzani AD; Bernardi F; Casarosa E; Pieri M; Palumbo M; Picciarelli G; Gabbanini M; Luisi M; Genazzani AR
    Gynecol Endocrinol; 2005 Mar; 20(3):144-9. PubMed ID: 16019353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.